Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.
2003 Apr
Journal Article
Authors:
Freeman, A.Krupnick;
Linowski, G.J.;
Brady, C.;
Lind, L.;
VanVeldhuisen, P.;
Singer, G.;
Lebwohl, M.
Secondary:
J Am Acad Dermatol
Volume:
48
Pagination:
564-8
Issue:
4
PMID:
12664020
Keywords:
Administration, Topical; Adult; Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ointments; Psoriasis; Tacrolimus
Abstract:
The safety and efficacy of 0.1% tacrolimus ointment for the treatment of psoriasis on the face, intertriginous areas, or both were evaluated in an open-label, clinical trial of 21 patients with psoriasis. Patients applied 0.1% tacrolimus ointment twice daily for 8 weeks. Efficacy was assessed through the investigator's evaluation of the individual signs and symptoms of psoriasis, and the physician's global evaluation of change in disease status. Assessments of cutaneous atrophy and other adverse events were made throughout the study to evaluate the safety of tacrolimus ointment. A total of 21 patients were enrolled in the study; 21 patients at least 18 years of age received study medication. Statistically significant improvement in the physician's assessment of the individual signs and symptoms was observed during the study. A total of 81% of patients (17 of 21) experienced complete clearance at day 57 (end of treatment). Only 2 patients reported adverse events, which were limited to itching and the feeling of warmth at the application site. None of the patients had atrophy, telangiectasia, or striae develop during the study. In summary, tacrolimus 0.1% ointment may be a safe and effective treatment option for patients with psoriasis on the face, intertriginous areas, or both.
